Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat versus standard Fabry therapy for left ventricular mass index in adults with Fabry disease
NL-OMON59181Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of venglustat in Fabry disease (FD) (2 arms), sponsored by Sanofi. Primary endpoint: Slope of left ventricular mass index. Started May 2023; status: active, not recruiting.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON59181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59181.